Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Emms takes up ABPI presidency

He succeeds MSD’s Deepak Khanna at the UK pharma industry body

Jonathan Emms, ABPIPfizer's UK managing director Jonathan Emms has taken up the role of president of the Association of the British Pharmaceutical Industry (ABPI).

Emms (pictured right) was elected to the position at the pharma industry body in December 2013 and will now serve for one year with the option of standing for re-election.

He takes over from MSD's Deepak Khanna who spent two years as president, working alongside CEO Stephen Whitehead to improve the image of the industry in the UK and represent its companies in issues such as the value-based pricing debate and the implementation of a new NHS commissioning system in England.

Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK.

He has not been afraid to criticise the outcomes of these discussions too, saying in November that the revised drug pricing scheme announced by the Department of Health was a “missed opportunity for British patients, the UK economy and industry”.

These concerns about access to new medicines were reiterated by Emms in a statement on what he hopes to achieve in his new role.

“High barriers to getting innovative medicines to patients and low and slow usage across the NHS means we risk falling behind our European neighbours. As president, I want to tackle the challenges head on and work together – industry, government and NHS – to make change happen.”

14th April 2014

From: Research, Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics